Vaping startup Respira Technologies has announced the launch of its RespiRx delivery device platform, which the company is aiming at pharmaceutical drug delivery “across the fullest spectrum of pressure and thermo sensitive APIs.” The company, which has backing from several venture capital companies, says that it is now a “a platform device and biotechnology company with a focus on aerosol science.”
According to the company, the RespiRx device is an “orientation agnostic,” handheld, programmable, connected vibrating mesh nebulizer that includes a disposable piezo element and utilizes a cartridge filled with an inhalation solution, which it says “eliminates the opportunity for patient error and misuse due to lack of proper cleaning.”
Respira Technologies Founder and CEO Mario Danek claims that, “The current landscape of drug delivery platforms lacks the patient focused attributes necessary to address the high rate of patient misuse of daily controller medications, including nebulizers. The RespiRx was created to address the patient’s unmet needs for improved care. The current landscape of medical aerosolizing devices being offered for treatment today, require ongoing cleaning and maintenance by the user and often are lacking in features such as Bluetooth-enabled mobile applications for real time accurate dose measurement — all of which the RespiRx provides.”
Danek has applied for a number of patents related to a cartridge-based inhalation device. He is also the co-founder of a company called Inhale Health that sells vape pens that deliver melatonin, vitamin B12, and caffeine.
Read the Respira Technologies press release.
